Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001247744 | SCV001421184 | uncertain significance | Rhabdoid tumor predisposition syndrome 2 | 2019-10-15 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has not been reported in the literature in individuals with SMARCA4-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces glutamic acid with lysine at codon 1665 of the SMARCA4 protein (p.Glu1665Lys). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and lysine. |